New oral drug tested for Hard-to-Treat bowel disease
NCT ID NCT05570006
Summary
This study tested an experimental oral medication called ABBV-668 for adults with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. About 30 participants took capsules twice daily for 16 weeks to see if the drug could reduce intestinal inflammation and improve symptoms like bleeding and frequent stools. Researchers measured safety and whether participants' colon lining looked healthier after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allegheny Singer Research Institute d/b/a AHN Research Institute /ID# 250079
Pittsburgh, Pennsylvania, 15212, United States
-
Atlantic Medical Research /ID# 249213
Margate, Florida, 33063-5737, United States
-
Atrium Health /ID# 249273
Charlotte, North Carolina, 28204-2963, United States
-
Baylor College of Medicine /ID# 249203
Houston, Texas, 77030, United States
-
CHU Grenoble - Hopital Michallon /ID# 252108
La Tronche, Isere, 38700, France
-
CHU Montpellier - Hopital Saint Eloi /ID# 251876
Montpellier, Herault, 34295, France
-
Centre Hospitalier Universitaire de Saint Étienne - Hôpital Nord /ID# 251875
St-Priest-en-Jarez, Pays de la Loire Region, 42270, France
-
Centre Medico Chirurgical Ambroise Pare Hartmann /ID# 252357
Neuilly-sur-Seine, Île-de-France Region, 92200, France
-
Columbia University Medical Center /ID# 250189
New York, New York, 10032-3729, United States
-
Ctr for Advanced Gastroenterol /ID# 249226
Maitland, Florida, 32751-6108, United States
-
Digestive Health Associates of Texas (DHAT) Research Institute - Garland /ID# 249208
Garland, Texas, 75044, United States
-
Endoscopic Research, Inc. /ID# 249202
Orlando, Florida, 32803, United States
-
Endoskopia Sp. z o.o. /ID# 255667
Sopot, Pomeranian Voivodeship, 81-756, Poland
-
Gastro SB /ID# 249271
Chula Vista, California, 91910-5619, United States
-
Gastroenterology Associates of Central Georgia, LLC /ID# 249278
Macon, Georgia, 31201, United States
-
Gastroenterology Associates, P.A. of Greenville /ID# 249217
Greenville, South Carolina, 29607, United States
-
Gastromed Sp. z o.o /ID# 255664
Torun, Kuyavian-Pomeranian Voivodeship, 87-100, Poland
-
Groupe Sante CHC - Clinique du MontLegia /ID# 248928
Liège, 4000, Belgium
-
H-T Centrum Medyczne Endoterapia /ID# 255666
Tychy, Silesian Voivodeship, 43-100, Poland
-
Lenox Hill Hospital /ID# 250008
New York, New York, 10075, United States
-
Medical Network Sp.z.o.o. WIP Warsaw IBD Point Profesor Kierkus /ID# 255663
Warsaw, Masovian Voivodeship, 00-728, Poland
-
NYU Langone Long Island Clinical Research Associates /ID# 250075
Lake Success, New York, 11042, United States
-
Options Health Research, LLC /ID# 249216
Tulsa, Oklahoma, 74104, United States
-
Quality Medical Research /ID# 251125
Nashville, Tennessee, 37211, United States
-
Southern Star Research Institute, LLC /ID# 249212
San Antonio, Texas, 78229-5390, United States
-
UZ Gent /ID# 248605
Ghent, Oost-Vlaanderen, 9000, Belgium
-
Universitair Ziekenhuis Leuven /ID# 248598
Leuven, Vlaams-Brabant, 3000, Belgium
-
University of Pennsylvania /ID# 250012
Philadelphia, Pennsylvania, 19104-5502, United States
-
University of Pittsburgh MC /ID# 250071
Pittsburgh, Pennsylvania, 15260, United States
-
Vitaz /Id# 248607
Sint-Niklaas, Oost-Vlaanderen, 9100, Belgium
Conditions
Explore the condition pages connected to this study.